Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
一项针对18至55岁健康成年人的随机、双盲、安慰剂对照I期试验，评估了联合肌注/鼻内给药重组刺突蛋白COVID-19疫苗（RCP）的免疫原性和安全性。
期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines11020455
Dodaran, Masoud Solaymani; Banihashemi, Seyed Reza; Es-Haghi, Ali; Mehrabadi, Mohammad Hossein Fallah; Nofeli, Mojtaba; Mokarram, Ali Rezaei; Mokhberalsafa, Ladan; Sadeghi, Fariba; Ranjbar, Alireza; Ansarifar, Akram; Mohazzab, Arash; Setarehdan, Seyed Amin; Bagheri Amiri, Fahimeh; Mohseni, Vahideh; Hajimoradi, Monireh; Ghahremanzadeh, Neda; Razzaz, Seyed Hossein; Masoomi, Safdar; Taghdiri, Maryam; Bagheri, Mohsen; Lofti, Mohsen; Khorasani, Akbar; Ghader, Masoud; Safari, Shiva; Shahsavn, Masumeh; Kalantari, Saeed
